menu
    • menu

    Company profile for Amplia Therapeutics

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Amplia Therapeutics Limited (ASX: ATX) is an Australian, publicly-listed, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.​ Amplia’s pipeline drugs were originally developed by the Cancer Therapeutics CRC (CTx), an Australian industry/academic collaboration that included leading c...
    Amplia Therapeutics Limited (ASX: ATX) is an Australian, publicly-listed, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.​ Amplia’s pipeline drugs were originally developed by the Cancer Therapeutics CRC (CTx), an Australian industry/academic collaboration that included leading cancer and medicinal chemistry researchers at Australia’s top cancer research institutes. Amplia was established to advance these promising drugs into clinical development and commercialisation.​

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Amplia TherapeuticsAustralia Flag
    Country
    Country
    Australia
    Address
    Address
    Level 21 90 Collins Street Melbourne VIC 3000
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ampliatx.com/site/content/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/amplia-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ampliatx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amplia Therapeutics Enhances Accent Pancreatic Cancer Trial
    Amplia Therapeutics Enhances Accent Pancreatic Cancer Trial

    23 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/23/3260403/0/en/Amplia-Therapeutics-Reports-Four-Additional-Complete-Responses-and-Improved-Overall-Survival-Data-in-Accent-Pancreatic-Cancer-Trial.html

    GLOBENEWSWIRE
    23 Mar 2026
    Share Share
    Narmafotinib Shows Combo Benefits in KRAS Models
    Narmafotinib Shows Combo Benefits in KRAS Models

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251847/0/en/Poster-Presentation-Demonstrating-Combination-Benefit-of-Narmafotinib-in-Preclinical-Kras-Mutated-Cancer-Models.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Amplia Opens U.S. Sites for Amplicity Pancreatic Cancer Trial
    Amplia Opens U.S. Sites for Amplicity Pancreatic Cancer Trial

    11 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/11/3236299/0/en/Amplia-Therapeutics-Announces-Opening-of-US-Sites-for-Amplicity-Pancreatic-Cancer-Trial.html

    GLOBENEWSWIRE
    11 Feb 2026
    Share Share
    Amplia Therapeutics Releases Q3 Activities and Cash Flow Report
    Amplia Therapeutics Releases Q3 Activities and Cash Flow Report

    30 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/30/3229545/0/en/Amplia-Therapeutics-Quarterly-Activities-and-Cash-Flow-Reports-December-2025.html

    GLOBENEWSWIRE
    30 Jan 2026
    Share Share
    Narmafotinib Large-Scale Manufacturing Complete
    Narmafotinib Large-Scale Manufacturing Complete

    22 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/22/3223746/0/en/NARMAFOTINIB-Large-Scale-Manufactre-Complete.html

    GLOBENEWSWIRE
    22 Jan 2026
    Share Share
    ACCENT DATA Showcased AT 2026 ASCO GI Cancer Symposium
    ACCENT DATA Showcased AT 2026 ASCO GI Cancer Symposium

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216936/0/en/ACCENT-DATA-PRESENTED-AT-2026-ASCO-GASTROINTESTINAL-CANCER-SYMPOSIUM.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search